Evidence has shown that these agents have greatly improved survival of NSCLC patients without driver mutations by blocking the interaction of PD-1 with its ligands (PD-L1 and PD-L2), thereby helping reverse T-cell anergy, exhaustion, and apoptosis (2, 3). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.